Tung‐Min Yu

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study

Tung‐Min Yu, Ya‐Wen Chuang, Mei‐Ching Yu et al. · The Lancet Oncology · 2016 · 102 citations

Urology, Oncology, Cancer Epidemiology +12

RANTES mediates kidney ischemia reperfusion injury through a possible role of HIF-1α and LncRNA PRINS

Tung‐Min Yu, Kalaiselvi Palanisamy, Kuo‐Ting Sun et al. · Scientific Reports · 2016 · 86 citations · Full text

Osteoporosis and Fractures After Solid Organ Transplantation

Tung‐Min Yu, Cheng‐Li Lin, Shih‐Ni Chang et al. · Mayo Clinic Proceedings · 2014 · 58 citations

Bone Disease, Skeletal Trauma, Solid Organ Transplantation +4